ReviewThorax1993
Cytokines and pulmonary fibrosis.
Review in Thorax, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 173 citations in OpenAlex.
- TRAF2 regulates the progression of pulmonary fibrosis through β-catenin-Snail signaling pathway.Frontiers in public health · 2025Article
- Idiopathic pulmonary fibrosis (IPF): disease pathophysiology, targets, and potential therapeutic interventions.Molecular and cellular biochemistry · 2024Review
- Advanced Delivery Strategies of Nintedanib for Lung Disorders and Beyond: A Comprehensive Review.AAPS PharmSciTech · 2024Review
- Revolutionizing the Treatment of Idiopathic Pulmonary Fibrosis: From Conventional Therapies to Advanced Drug Delivery Systems.AAPS PharmSciTech · 2024Review
- Therapeutic potential of melatonin in targeting molecular pathways of organ fibrosis.Pharmacological reports : PR · 2024Review
- Coal dust nanoparticles induced pulmonary fibrosis by promoting inflammation and epithelial-mesenchymal transition via the NF-κB/NLRP3 pathway driven by IGF1/ROS-mediated AKT/GSK3β signals.Cell death discovery · 2022Article
- Humoral Immune Status in Relation to Outcomes in Patients with Idiopathic Pulmonary Fibrosis.Lung · 2021Article
- Curcumin inhibition of bleomycin-induced changes in lung collagen synthesis, deposition and assembly.Molecular biology reports · 2021Article
- Transforming Growth Factor-β1 in predicting early lung fibroproliferation in patients with acute respiratory distress syndrome.PloS one · 2018Article
- Safety and Efficacy of Allogeneic Lung Spheroid Cells in a Mismatched Rat Model of Pulmonary Fibrosis.Stem cells translational medicine · 2017Article
- Dynamic expression of transformating growth factor-β1 and caveolin-1 in the lung of Bleomycin-induced interstitial lung disease.Journal of thoracic disease · 2017Article
- Secretory leukocyte protease inhibitor gene deletion alters bleomycin-induced lung injury, but not development of pulmonary fibrosis.Laboratory investigation; a journal of technical methods and pathology · 2016Article
- Lung Infection by Human Bocavirus Induces the Release of Profibrotic Mediator Cytokines In Vivo and In Vitro.PloS one · 2016Article
- Pathobiology of wound healing after glaucoma filtration surgery.BMC ophthalmology · 2015Review
- The ameliorative effect of silibinin against radiation-induced lung injury: protection of normal tissue without decreasing therapeutic efficacy in lung cancer.BMC pulmonary medicine · 2015Article
- Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report.BMC musculoskeletal disorders · 2015Article
- Salidroside alleviates paraquat-induced rat acute lung injury by repressing TGF-β1 expression.International journal of clinical and experimental pathology · 2014Article
- Extracellular superoxide dismutase in pulmonary fibrosis.Antioxidants & redox signaling · 2008Review
- Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features.Clinical and experimental immunology · 2003Article
- Activation of type II alveolar epithelial cells during acute endotoxemia.American journal of physiology. Lung cellular and molecular physiology · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronically inflamed and fibrotic tissue of the respiratory tract can be shown to actively express the genes and products of a number of powerful growth and differentiating factors. The initial activation of lung inflammatory cells, including alveolar macrophages, is presumed to result in the release of early acting cytokines such as IL-1 and TNF. Subsequent activation and possible phenotype alteration of the structural cells results in release of other growth factors and accumulation of blood derived inflammatory cells. These cells, once they have entered the tissue and become further activated, may begin to release their own autocrine factors and "feed back" some of the similar signals to the tissue cells in a paracrine manner, further inducing differentiation and phenotype change. These internal tissue cell and cytokine cascades could account for the chronic nature of the inflammation. Therapeutic intervention must therefore take into account the inflammatory component as well as the nature of the cytokines and structural cells involved in the propagation of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.